Rubella virus vaccine, live Subcutaneous and Tolterodine Tartrate

• Generic Name: rubella virus vaccine
• Dosage Forms: n.a.
• Other Brand Names:

Rubella virus vaccine live is an active immunizing agent used to prevent infection by the rubella virus. It works by causing your body to produce its own protection (antibodies) against the virus infection.

Rubella (also known as German measles) is a serious infection that causes miscarriages, stillbirths, or birth defects in unborn babies when pregnant women get the disease. While immunization against rubella is recommended for everyone, it is especially important for women of child-bearing age.

Immunization against rubella is also important for employees in medical facilities, adolescents and adult men, persons traveling outside the U.S., and all children 12 months of age and older, including school-aged children.

Immunization against rubella is not recommended for infants less than 12 months of age, because antibodies they received from their mothers before birth may interfere with the effectiveness of the vaccine. Children who were immunized against rubella before 12 months of age should be immunized again.

You can be considered immune to rubella only if you received rubella vaccine on or after your first birthday and have the medical record to prove it, or if you have had a blood test showing immunity to rubella. A past history of having a rubella infection does not prove immunity, because the signs of rubella infection are not reliable enough to be certain that you have had the disease.

Since vaccination with rubella vaccine may not provide protection for everyone, you may want to ask your doctor to check your immunity to the rubella virus 6 to 8 weeks following your vaccination. This may be especially important if you are a woman of child-bearing age who is likely to become pregnant in the future.

This vaccine is to be administered only by or under the supervision of your doctor or other health care professional.

• Generic Name: tolterodine
• Dosage Forms: n.a.
• Other Brand Names: Detrol, Detrol LA

Treatment of overactive bladder for the relief of symptoms associated with voiding such as urge urinary incontinence, urgency, and frequency. Efficacy not established in pediatric patients.

Tolterodine (conventional tablets) appears to be as effective as conventional oxybutynin in reducing urinary symptoms in patients with overactive bladder and is associated with a lower incidence of dry mouth.

Tolterodine (2 mg twice daily as conventional tablets) appears to be less effective than extended-release oxybutynin (10 mg once daily as extended-release tablets) in reducing urinary symptoms in patients with overactive bladder. The incidence of adverse effects (e.g., dry mouth) is similar between conventional tolterodine tartrate and extended-release oxybutynin.

Single daily doses of extended-release capsules of tolterodine tartrate appear to be slightly more effective in relieving certain urinary symptoms (i.e., urge incontinence) than 2 daily doses of conventional tablets of the drug.